Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice

BACKGROUND AND AIMS: Vedolizumab inhibits leucocyte vascular adhesion and migration into the gastrointestinal tract through α4β7 integrin blockade. This agent became available in mid-2014 for the treatment of moderate to severe Crohn’s disease (CD) and UC (UC). The aim of this study was to assess th...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Crohns Colitis
Main Authors: Vivio, Emily E., Kanuri, Navya, Gilbertsen, Joanna J., Monroe, Kelly, Dey, Neelendu, Chen, Chien-Huan, Gutierrez, Alexandra M., Ciorba, Matthew A.
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2016
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4946762/
https://ncbi.nlm.nih.gov/pubmed/26681763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjv226
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker